Quantitative analysis of plasma HBV DNA for early evaluation of the response to transcatheter arterial embolization for HBV-related hepatocellular carcinoma

Table 1 Basic characteristics before TAE and lipiodol retention percentage after TAE of group I and group II patients

	Group I(n=6)	Group II(n=7)	P
Age, year (range)	57.6 (39-79)	65.6 (38 – 81)	0.34
Gender (male/female)	6/0	5/2	-
Pretreatment AFP (ng/ml)	707 ±1536	3024 ±5307	0.32
Tumor size (cm)	5.92 ± 3.98	5.00 ± 2.20	0.61
Disease status at entry			-
For the first time TAE (n)	3	2
For recurrence (n)	3	5
Lipiodol retention (%)	79.31 ± 28.79	18.43 ± 10.61	0.02a

n: patient number. Statistical data are expressed as mean±SD.

^aP<0.05, with statistical significance.